//
Livius Penter
Alexandra Savell
Srinika Ranasinghe
Teddy Huang
Nicoletta Cieri
Satyen H Gohil
Wandi Zhang
Shuqiang Li
Robert Zeiser
Haesook T. Kim
Kenneth J. Livak
Jerome Ritz
Donna S. Neuberg
Robert J. Soiffer
X. Shirley Liu
Matthew S. Davids
Pavan Bachireddy
Catherine J. Wu
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin,Berlin,Allemagne
Harvard Medical School, Boston, MA
Broad Institute of MIT and Harvard, Cambridge, MA
Department of Imaging, Dana-Farber Cancer Institute, Boston, MA
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Center for Neuro-Oncology at Dana-Farber Cancer Institute, Boston, MA
Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
Department of Haematology, University College London Cancer Institute,London,United Kingdom
Medical Faculty University of Freiburg, Freiburg Im Breisgau, GA, Germany
Department of Medicine, Brigham and Women's Hospital, Boston, MA
Department of Medicine, Brigham and Women's Hospital, Boston, MA
United States
Germany
United Kingdom
N/A
Autoimmune (AI)
Graft-versus-host disease
Cluster of Differentiation 4
Programmed death-ligand 1
Cluster of differentiation 8A
Human Leukocyte Antigen – DR isotype
Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon
T-cell receptor
Ipilimumab
Nivolumab
N/A
N/A
NA
N/A
N/A
N/A